Skip to content
Review Open access

Advanced Therapies for the Management of Immune Checkpoint Inhibitor-Induced Colitis

Sep 2026 · Cancers · Vol 18 · 0 citations · 76 references
Medicine

Abstract

Simple Summary Immune checkpoint inhibitors help the body’s immune system attack tumors and have greatly improved survival for many cancer patients. However, by boosting the immune system, these drugs can also cause it to attack healthy tissue, and inflammation of the bowel is one of the most common and serious side effects. Steroids are usually given first, but they do not work for many patients or can cause their own problems with long-term use. Other drugs, originally developed for bowel diseases such as Crohn’s disease and ulcerative colitis, are increasingly used instead, but gaps of evidence persist on which drug to choose, in what order, and whether these treatments might weaken the cancer drug’s effect.

Read PDF

Similar papers

Review Open access Oct 2026

Type 1 diabetes mellitus during immune checkpoint inhibitor therapy in cancer patients

The development of immune checkpoint inhibitors (ICIs) has led to significant changes in the treatment strategies for malignant tumors. Results from numerous randomized trials of this class of drugs, alongside their widespread adoption in clinical practice, have demonstrated superior therapeutic efficacy in patients wi...

R. Orlova, I. V. Gerk, I. Itkin et al. · 0 citations
Review Open access Oct 2026

Cancer Immunotherapy and Immune-Related Adverse Events: Focusing on Non-Small Cell Lung Cancer

Simple Summary Immunotherapy harnesses the power of the patient’s own immune system to target and destroy cancer cells. As an important type of immunotherapy, immune checkpoint inhibitors have changed the landscape of cancer therapy and significantly improved patient outcomes. However, only some patients respond to imm...

Atif Kamil, Sara Cowles, Casaundra C. Driver et al. · 0 citations
Review Oct 2026

Precision toxicity control in checkpoint immunotherapy.

Immune checkpoint inhibitors have changed cancer management. However, immune-related adverse events (irAEs) can disrupt treatment and limit effective combination strategies. The standard of care tends to involve broad immunosuppression, which may compromise antitumor immunity and fail to address the dominant biology of...

Zhen Sun, Xiao-Yi Yang, Wei-Ming Shen et al. · 1 citation
Review Open access Oct 2026

Cellular Therapy in Inflammatory Bowel Diseases

Despite significant advances in understanding the biology of inflammatory bowel diseases (IBD), the underlying etiology is still unknown, and currently available treatment options are not curative. Furthermore, even after the advent of multiple targeted “advanced” therapies, approximately one-third of patients do not r...

Samuel Majna, B. Brezina, M. Sharip et al. · 0 citations
Editorial Open access Oct 2026

Editorial: Chemoresistance and immunotherapy in solid tumors

This Research Topic set out to examine immune and stromal mechanisms of chemoresistance, useful biomarkers, and improve combination treat-ment, and addresses different parts of that problem, from tumor-cell survival to drug delivery, response, and toxicity.

Jun-Chao Xu · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.